Twist Bioscience (NASDAQ:TWST) Given New $55.00 Price Target at Guggenheim

Twist Bioscience (NASDAQ:TWST) had its target price upped by Guggenheim from $50.00 to $55.00 in a research report issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Guggenheim’s target price suggests a potential upside of 23.13% from the company’s previous close.

Several other research analysts also recently issued reports on TWST. Barclays raised their price objective on shares of Twist Bioscience from $39.00 to $50.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 3rd. Robert W. Baird set a $50.00 target price on shares of Twist Bioscience in a research note on Tuesday, February 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a report on Friday. TD Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a research note on Thursday, January 8th. Finally, Evercore increased their price objective on Twist Bioscience from $42.00 to $52.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 3rd. Seven equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $46.50.

Twist Bioscience Stock Performance

TWST traded up $0.14 during trading on Monday, hitting $44.67. 148,096 shares of the stock were exchanged, compared to its average volume of 1,307,907. The company has a quick ratio of 3.37, a current ratio of 3.78 and a debt-to-equity ratio of 0.03. Twist Bioscience has a 1-year low of $23.30 and a 1-year high of $57.88. The stock has a fifty day moving average price of $46.47 and a two-hundred day moving average price of $36.66. The firm has a market capitalization of $2.74 billion, a P/E ratio of -34.90 and a beta of 2.23.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.02). The firm had revenue of $103.70 million during the quarter, compared to analyst estimates of $100.32 million. Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. Twist Bioscience’s quarterly revenue was up 16.9% compared to the same quarter last year. As a group, sell-side analysts predict that Twist Bioscience will post -2.12 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Dennis Cho sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $49.93, for a total value of $249,650.00. Following the completion of the sale, the insider owned 138,581 shares in the company, valued at $6,919,349.33. This trade represents a 3.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Paula Green sold 935 shares of Twist Bioscience stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $46.43, for a total value of $43,412.05. Following the completion of the sale, the senior vice president directly owned 124,401 shares in the company, valued at $5,775,938.43. This represents a 0.75% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 48,190 shares of company stock valued at $2,234,695. Corporate insiders own 3.08% of the company’s stock.

Institutional Trading of Twist Bioscience

A number of institutional investors have recently modified their holdings of the business. Royal Bank of Canada grew its holdings in Twist Bioscience by 11.8% during the first quarter. Royal Bank of Canada now owns 40,373 shares of the company’s stock worth $1,585,000 after acquiring an additional 4,254 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Twist Bioscience by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,310 shares of the company’s stock worth $2,765,000 after purchasing an additional 3,181 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of Twist Bioscience by 4.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 932,978 shares of the company’s stock valued at $36,629,000 after purchasing an additional 37,577 shares in the last quarter. Intech Investment Management LLC increased its holdings in shares of Twist Bioscience by 18.9% in the 1st quarter. Intech Investment Management LLC now owns 28,917 shares of the company’s stock valued at $1,135,000 after purchasing an additional 4,591 shares in the last quarter. Finally, Legal & General Group Plc lifted its stake in shares of Twist Bioscience by 22.0% in the second quarter. Legal & General Group Plc now owns 110,286 shares of the company’s stock valued at $4,057,000 after purchasing an additional 19,915 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.